Themes / Group
Active · established relationshipLatest completed snapshot · Aug 21 · 16:11 ET

MARKET-DISCOVERED GROUP

Biotech Rare Diseases

THE TRADER READShared activity without a clean directional read

8 of 12 measured session-normalized paths align to the upside across 8.4 effective names. Common-bar coverage spans 12 of 18 cohort members. Capital-flow agreement is 17%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth10 up · 8 down+0.5% session-normalized median path
Capital-flow alignment17%Price breadth is not yet confirmed by flow
Activity nowHotActivity score 84/100 · lift 1.3×
Evidence depth3 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

5 timed events · 15:50–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. Retained observationGroup activity qualified live

    72% breadth · Hot activity

  2. 5-minute inferenceKRYS registered the first material upside path

    +2.28% session path at the threshold · KRYS

  3. 5-minute inferenceJAZZ registered a material upside path

    +2.28% session path at the threshold · JAZZ

  4. 5-minute inferenceCLDX registered a material upside path

    +2.70% session path at the threshold · CLDX

  5. 5-minute inferenceIMNM registered a material upside path

    +1.10% session path at the threshold · IMNM

2 earlier filing context receipts

TUE, NOV 4JAZZ filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

TUE, AUG 4ARQT filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

Session-normalized 5m paths

Observed movement is broad across 8.4 effective names. KRYS represents 19.8% of absolute path energy; 8 of 12 members align with the up relative path.

ConstructionBroad19.8% from the largest path
Effective names8.4 / 1212 of 18 cohort members had common bars
Direction breadth8/12 alignedupside relative path · 4 counter-moving
Largest moverKRYS 19.8%36.5% from the top two paths
KRYS19.8%Aligned contributor · path +2.68% · basket +0.22pp
JAZZ16.7%Aligned contributor · path +2.26% · basket +0.19pp
CLDX12.6%Aligned contributor · path +1.70% · basket +0.14pp
IMNM10.8%Aligned contributor · path +1.46% · basket +0.12pp
MIRM9.4%Counter-move · path -1.28% · basket -0.11pp
BLTE7.7%Counter-move · path -1.04% · basket -0.09pp
ARQT6.1%Counter-move · path -0.83% · basket -0.07pp
DYN5.1%Aligned contributor · path +0.69% · basket +0.06pp
NAMS4.5%Aligned contributor · path +0.61% · basket +0.05pp
LGND3.1%Counter-move · path -0.42% · basket -0.04pp
IMVT2.3%Aligned contributor · path +0.32% · basket +0.03pp
DNLI1.6%Aligned contributor · path +0.22% · basket +0.02pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. KRYS moved higher firstFirst member to clear the material path threshold · path +2.28%
  2. JAZZ registered a material higher path0m after the first price move · path +2.28%
  3. CLDX registered a material higher path0m after the first price move · path +2.70%
  4. IMNM registered a material higher path0m after the first price move · path +1.10%
  5. MIRM registered a material lower path0m after the first price move · path -1.20%
  6. BLTE registered a material lower path0m after the first price move · path -0.70%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

Session-normalized
Aug 20 · 15:50 ETMove visible 15:50 ETAug 21 · 15:55 ET
Group median +0.46%Strongest relative path KRYSWeakest relative path MIRM

Observed member paths normalized to the session. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

17/18 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across CLDX, DNLI, DYN, IMNM, JAZZ, KRYS, LGND, MIRM, NAMS, RYTM, SUPN, TGTX, TVTX, UTHR.

product pipeline / R&D affecting expense

“For 2025, we expect that our research and development expenses will decrease compared to 2024, primarily driven by a reduction in clinical studies and outside services costs relating to zanidatamab, JZP385 and continued portfolio prioritization, partially offset by the inclusion of costs associated with the development of Modeyso.”

JAZZ 10-Q · 2025-11-05
credit / rates affecting interest expense

“Interest Expense, Net Interest expense, net decreased by $10.3 million and $24.1 million in the three and six months ended June 30, 2026, compared to the same periods in 2025, primarily due to lower interest expense on the Tranche B-2 Dollar Term Loans and higher interest income as a result of higher cash reserves, offset by lower interest rates.”

JAZZ 10-Q · 2026-08-03
product pipeline / R&D

“In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.”

ARQT 10-K · 2026-02-25
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

ROIVNot confirming

IMNM · text peer

BMRNNot confirming

MIRM · text peer

SNGXNot confirming

TGTX · text peer

VRTXNot confirming

JAZZ · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
JAZZTGTXRYTMBLTESUPNMIRMNAMSUTHRTVTXIMNMARQTKRYSCLDXDYNLGNDIMVTPTCTDNLI

14/18 active10 rising · 8 falling

MemberUnusual activityToday's moveRead now
JAZZJazz Pharmaceuticals plc
Most unusual · 100/100
+2.2%
Aligned path contributorActive in 12.5% of observed group sessions
TGTXTG Therapeutics, Inc.
Elevated · 49/100
+7.3%
Active; unclassifiedActive in 12.5% of observed group sessions
RYTMRhythm Pharmaceuticals, Inc. Common Stock
Elevated · 29/100
+1.0%
Active; unclassifiedActive in 18.8% of observed group sessions
BLTEBelite Bio, Inc
Elevated · 27/100
-0.8%
Counter-move / dispersionActive in 21.9% of observed group sessions
SUPNSupernus Pharmaceuticals, Inc.
Elevated · 24/100
-3.2%
Active; unclassifiedActive in 6.2% of observed group sessions
MIRMMirum Pharmaceuticals, Inc.
Elevated · 23/100
-0.9%
Counter-move / dispersionActive in 6.2% of observed group sessions
NAMSNewAmsterdam Pharma Company N.V.
Elevated · 21/100
+0.2%
Aligned path contributorActive in 9.4% of observed group sessions
UTHRUnited Therapeutics Corporation
Elevated · 20/100
-1.4%
Flow confirmerActive in 6.2% of observed group sessions
TVTXTravere Therapeutics, Inc.
Elevated · 19/100
+2.0%
Flow confirmerActive in 28.1% of observed group sessions
IMNMImmunome, Inc.
Participating · 18/100
+1.6%
Aligned price + flowActive in 31.2% of observed group sessions
ARQTArcutis Biotherapeutics, Inc.
Participating · 17/100
-1.0%
Counter-move / dispersionActive in 18.8% of observed group sessions
KRYSKrystal Biotech, Inc. Common Stock
Participating · 17/100
+2.8%
Aligned path contributorActive in 18.8% of observed group sessions
CLDXCelldex Therapeutics, Inc.
Participating · 16/100
+1.1%
Aligned path contributorActive in 18.8% of observed group sessions
DYNDyne Therapeutics, Inc.
Participating · 15/100
+0.5%
Aligned path contributorActive in 21.9% of observed group sessions
LGNDLigand Pharmaceuticals Incorporated
Participating · 15/100
-0.4%
Counter-move / dispersionActive in 18.8% of observed group sessions
IMVTImmunovant, Inc.
Quiet · 12/100
+0.1%
Watch / laggardActive in 37.5% of observed group sessions
PTCTPTC Therapeutics, Inc.
Quiet · 12/100
-1.0%
Watch / laggardActive in 3.1% of observed group sessions
DNLIDenali Therapeutics Inc. Common Stock
Quiet · 10/100
-0.1%
Watch / laggardActive in 6.2% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
JAZZJazz Pharmaceuticals plcMost unusual+2.2%12.5% of 32 sessionsMost unusual activity in this snapshot; performance direction may differ.
TGTXTG Therapeutics, Inc.Participating+7.3%12.5% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
RYTMRhythm Pharmaceuticals, Inc. Common StockParticipating+1.0%18.8% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
BLTEBelite Bio, IncParticipating-0.8%21.9% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
SUPNSupernus Pharmaceuticals, Inc.Participating-3.2%6.2% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
MIRMMirum Pharmaceuticals, Inc.Participating-0.9%6.2% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
NAMSNewAmsterdam Pharma Company N.V.Participating+0.2%9.4% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
UTHRUnited Therapeutics CorporationParticipating-1.4%6.2% of 32 sessionsPrice participation with accumulating signed flow.
TVTXTravere Therapeutics, Inc.Participating+2.0%28.1% of 32 sessionsPrice participation with accumulating signed flow.
IMNMImmunome, Inc.Participating+1.6%31.2% of 32 sessionsPrice participation with accumulating signed flow.
ARQTArcutis Biotherapeutics, Inc.Participating-1.0%18.8% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
KRYSKrystal Biotech, Inc. Common StockParticipating+2.8%18.8% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
CLDXCelldex Therapeutics, Inc.Participating+1.1%18.8% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
DYNDyne Therapeutics, Inc.Participating+0.5%21.9% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
LGNDLigand Pharmaceuticals IncorporatedParticipating-0.4%18.8% of 32 sessionsPrice participation is not yet confirmed by per-name flow.
IMVTImmunovant, Inc.Quiet / lagging+0.1%37.5% of 32 sessionsNot participating yet; a breadth test or a genuine divergence.
PTCTPTC Therapeutics, Inc.Quiet / lagging-1.0%3.1% of 32 sessionsNot participating yet; a breadth test or a genuine divergence.
DNLIDenali Therapeutics Inc. Common StockQuiet / lagging-0.1%6.2% of 32 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Observed follow-through

7/7 events completed
30 minutes+0.05%50% continuation · n=4Median MFE +1.03% · MAE -0.31%
60 minutes+0.17%100% continuation · n=4Median MFE +1.03% · MAE -0.31%
Session close+0.38%100% continuation · n=3Median MFE +1.10% · MAE 0.00%
Next-session close+0.31%75% continuation · n=4Median MFE +1.03% · MAE -0.31%
Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 3 completed episodes across 32 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support43 daysHow often the cohort identity was observed
Completed episodes3Separate periods of broad group activity
Active sessions32Completed session observations, not trades
2026-07-07 → 2026-08-2127 active sessionsNo name was active through every recorded session
2026-06-26 → 2026-07-024 active sessionsNo name was active through every recorded session
2026-06-181 active session100% composition consistency through the episode
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
IMVT37.5% · 2 episodes
IMNM31.2% · 2 episodes
TVTX28.1% · 1 episode
BLTE21.9% · 1 episode
DYN21.9% · 2 episodes
ARQT18.8% · 1 episode
CLDX18.8% · 1 episode
KRYS18.8% · 1 episode
LGND18.8% · 1 episode
RYTM18.8% · 1 episode
JAZZ12.5% · 1 episode
TGTX12.5% · 1 episode
NAMS9.4% · 1 episode
DNLI6.2% · 1 episode
MIRM6.2% · 1 episode
SUPN6.2% · 1 episode
UTHR6.2% · 1 episode
PTCT3.1% · 1 episode